The potential clinical relevance of this work is highlighted by evidence that combinatorial blockade of TIGIT and other checkpoint receptors also enhances the effector function of ex vivo‐stimulated CD8+ TIL from melanoma patients as well as CD4+ and CD8+ T cells from acute lymphocytic leukemia patients, suggesting that such regimens are likely to show improvements over monotherapies in cancer patients as well.201, 205. The gene discussed is CD8A; the disease is melanoma.